T-cell responses as a correlate of COVID-19 vaccination. A pilot study in Health Care Workers - Martínez-Gallo, Mónica; Esperalba-Esquerra, Juliana; Pujol-Borrell, Ricardo; Sandá, Victor; Arrese-Muñoz, Iria; Fernández Naval, Candela; Antón Pagarolas, Andrés; Cardona, Victoria; Labrador-Horrillo, Moisés; Pumarola-Suñé, Tomás; Hernandéz-González, Manuel (medRxiv, 2021)
Background Clinical trials on the different vaccines to SARS-CoV-2 have demonstrated protection efficacy, but it is urgent to assess the levels of protection generated with real-world data, especially in individuals professionally exposed. Measuring T-cell responses may complement antibody tests currently in use as correlates of protection but there are not validated T cell response applicable to large number of samples.Objective To assess the feasibility of using T-cell responses to SARS-CoV-2 S peptides by commercially available whole blood interferon-gamma release assays (IGRA) as a correlate of protection.Patients Twenty health care workers before and after vaccination.Methods Antibody test to SARS-CoV-2 N and S proteins in parallel with one IGRA assay and two detection techniques than can be automated.Results IGRA test detected T-cell responses in naturally exposed and vaccinated HCW already after first vaccination dose. the correlation by the two detection methods, CLIA and ELISA, very high (R>0.9) and sensitivity and specificity ranged between 100 and 86% and 100-73% respectively. Even though there was a very high concordance between antibody and the IGRA assay in the ability to detect immune response to SARS-CoV-2 there was a relatively low quantitative correlation. In the small group primed by natural infection, one vaccine dose was sufficient to reach immune response plateau. IGRA was positive in one Ig (S) antibody negative vaccinated immunosuppressed HCW illustrating another advantage of the IGRA test.Conclusion Whole blood IGRA tests amenable to automation, as the one here reported, constitute a promising additional tool for measuring the state of the immune response to SARS-CoV-2; they are applicable to large number of samples and may become valuable correlates of protection to COVID-19, particularly for vulnerable groups at risk of being re-exposed to infection, as are health care workers.Clinical Implications Commercial kits of whole blood Interferon-gamma release assay (IGRA) constitute an reliable method for clinical laboratories to assess T-cell response after natural infection by SARS-CoV-2 and after BNT162b2 mRNA vaccination and are suitable for large scale application.Key MessagesCommercial kits of whole blood interferon-gamma release assay (IGRA) are potentially very useful tools to measure the T cell response to SARS-CoV-2 after COVID-19 and after SARS-CoV-2 vaccination.One vaccine dose restores T cell response in COVID recovered patients, but the vaccination boost was required for naïve participants to attain a comparable response.T cell response seem to decay in COVID recovered subjects after the boost second vaccination dose.Capsule Summary Measuring T cell responses by commercially available whole blood interferon gamma release assays (IGRA) provide a promising additional correlate of protection to COVID and may be useful to reassure vulnerable group professionals at risk of being exposed to SARS-CoV-2 infection.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded in part by Instituto de Salud Carlos III, grant COV20/00416 co-financed by the European Regional Development Fund (ERDF).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This project was approved by the Hospital Universitari Vall d,Hebron Institutional Clinical Ethical Board. (HUVH PR(AG)113/2021).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Yes27-March-2021(HCWs)Health care workers(IGRA)Interferon-gamma release assays(CLIA)Chemiluminescence immunoassays(ELISA)Enzyme linked immunosorbent assay(CBC)Complete blood count(S)Spike protein(N)Nucleocapsid protein